Skin Cancer

An expert weighs in on what to know about the uncommon skin cancer

Health news and commentary from around the Web gathered by MedPage Today staff

Differences between patients and volunteers, early- vs late-stage may help guide management

Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option

Studies show their potential, but reveal clear issues with treatment information reliability

Retrospective data suggest superior survival in pathologically confirmed node-negative disease

Hepzato Kit melphalan delivery system produced objective responses in 36% of patients

Absolute risk reduction of 9-10% in 1- and 2-year DFS compared with observation

Sensitivity, specificity, mean accuracy, and AUC improved significantly with neural network input

Results will likely "encourage a practice change," editorialists say

Also in TTHealthWatch: chronic pain in U.S. adults, and a new treatment for C. diff

"One of the highest tumor response rates we've seen in any cancer," study discussant says

Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies

Both sides likely to appeal the ruling